newsfilter
← Latest News
GlobeNewswire·

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company's lead product candidate – nemvaleukin alfa – being developed to treat a wide